Amgen and Novartis have announced a partnership for the development of BACE inhibitor drugs, including CNP520, which is being used in the Alzheimer’s Prevention Initiative (API) APOE4 trial. This significant investment demonstrates the esteem in with which the API is held and furthers our collaborative efforts to prevent Alzheimer’s disease. You can view the announcement here: http://www.
Major media coverage of the announcement includes stories in the LA Times and Reuters:
LA Times
Amgen and Novartis partnering on a drug that could prevent Alzheimer’s<http://www.
Reuters
Novartis, Amgen join forces to fight Alzheimer’s and migraine<http://www.reuters.
